Quad screen; Multiple marker screening; AFP plus; Triple screen test; AFP maternal; MSAFP; 4-marker screen
The quadruple screen test is a blood test done during pregnancy to determine whether the baby is at risk for certain birth defects.
This test is usually performed between the 15th and 22nd weeks of the pregnancy, but it is most accurate between the 16th and 18th weeks.
Blood is typically drawn from a vein, usually from the inside of the elbow or the back of the hand. The site is cleaned with germ-killing medicine (antiseptic). The health care provider wraps an elastic band around the upper arm to apply pressure to the area and make the vein swell with blood.
Next, the health care provider gently inserts a needle into the vein. The blood collects into an airtight vial or tube attached to the needle. The elastic band is removed from your arm. Once the blood has been collected, the needle is removed, and the puncture site is covered to stop any bleeding.
The blood sample is sent to a laboratory for testing.
The test measures levels of four substances:
If the test does not measure levels of inhibin A, it is called the triple screen test.
To determine the chance of your baby having a birth defect, the test also factors in:
No special preparation is necessary.
When the needle is inserted to draw blood, some people feel moderate pain, while others feel only a prick or stinging sensation. Afterward, there may be some throbbing.
To find out if your baby might be at risk for certain birth defects, such as Down syndrome and neural tube defects.
ACOG Committee on Practice Bulletins. ACOG practice bulletin no. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109:217-227.
Graves JC, Miller KE. Maternal serum triple analyte screening in pregnancy. Am Fam Physician. 2002;65:915-920, 922.